Vavricka John's Form 4 filing
Atea Pharmaceuticals, Inc. (AVIR) · filed Feb 2, 2024
- Accession no.
- 0000950170-24-010968
- Filed
- Feb 2, 2024
- Trade date
- Jan 31-Feb 1, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $45.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vavricka JohnCIK 0001829630 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Common Stock | MOption exerciseAcquired | +33,334 | – | – | 33,334 | Direct | |
| Feb 1, 2024 | Common Stock | SSaleDisposed | −11,819 | $3.84 | −$45,384.96 | 21,515 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Common Stock | MOption exerciseDisposed | −33,334 | $0.00 | $0 | 66,666 | Direct | |
| Jan 31, 2024 | Common Stock | AGrant or awardAcquired | +132,800 | $0.00 | $0 | 132,800 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.